NRC · XBRL financial data

NRC Health financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NRC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	133,277	147,954	151,568	148,580	143,060	137,390
Selling, general and administrative	34,441	38,960	42,699	46,621	44,911	54,805
Operating income (loss)	42,677	50,270	46,543	40,045	35,194	22,590
Interest income	18	14	168	820	125	111
Interest expense	1,813	1,667	1,209	862	2,595	4,761
Other income (expense)	585	4	(118)	(41)	(34)	(95)
Income tax expense (benefit)	4,207	11,155	11,015	8,991	7,907	6,245
Earnings per share, basic USD per share	1.48	1.47	1.28	1.26	1.05	50.00
Earnings per share, diluted USD per share	1.45	1.46	1.27	1.25	1.04	50.00
Weighted average shares, basic thousands of shares	25,170	25,422	24,922	24,540	23,703	22,383
Weighted average shares, diluted thousands of shares	25,696	25,640	25,052	24,673	23,743	22,396

Fiscal years (NRC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	34,690	54,361	25,026	6,653	4,233	4,139
Accounts receivable	13,923	13,728	14,461	12,378	11,054	11,108
Total current assets	54,112	73,707	43,716	24,360	19,600	20,209
Property and equipment, net	11,726	12,391	17,248	28,205	38,269	—
Right-of-use asset	1,308	975	556	2,060	1,627	1,157
Goodwill	57,255	61,614	61,614	61,614	66,152	66,152
Total assets	133,423	157,540	130,461	122,437	132,539	134,878
Accounts payable	1,095	1,943	1,153	1,301	1,194	1,169
Accrued liabilities	3,184	5,450	3,983	4,893	5,091	2,897
Current portion of long-term debt	—	—	—	—	—	4,014
Total current liabilities	31,681	40,388	33,417	36,203	35,858	36,620
Long-term debt	26,547	—	—	29,470	57,895	75,021
Lease liability, non-current	—	—	—	1,650	1,156	744
Total liabilities	69,108	72,203	58,428	73,482	101,255	120,888
Accumulated deficit	(61,375)	(36,112)	(25,184)	(30,530)	(17,064)	(17,298)
Total stockholders' equity	64,315	85,337	72,033	48,955	31,284	13,990
Total liabilities and equity	133,423	157,540	130,461	122,437	132,539	134,878
Common shares outstanding (cover page) thousands of shares	25,420	25,194	24,594	23,854	22,946	22,746

Fiscal years (NRC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Stock-based compensation	680	623	1,200	935	284	3,312
Net cash from operating activities	40,636	46,344	36,265	38,113	34,625	26,450
Purchases of property and equipment	3,984	5,514	9,835	15,779	15,448	10,706
Net cash from investing activities	(3,724)	(8,514)	(9,835)	(15,778)	(20,281)	(10,706)
Share repurchases	—	4,142	27,616	19,099	30,945	20,180
Dividends paid	10,517	9,159	20,961	36,366	11,453	10,978
Net cash from financing activities	(15,503)	(18,162)	(55,583)	(40,707)	(16,764)	(15,838)
Net change in cash	21,173	19,671	(29,335)	(18,373)	(2,420)	(94)

SIC 8731 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8731 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
NRC Health	3,327	35,392	1,386*	22.1M	—	Q2 FY26 10-QJun 30, 2026
Maxcyte	15,042	7,271	(4,661)*	103.2M	22.7 quarters	Q2 FY26 10-QJun 30, 2026
OmniAb	22,883	3,993	10,575*	145.9M	—	Q3 FY26 10-QSep 30, 2026
Absci	107,865	not reported	(27,564)*	171.6M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
Inotiv	15,180	117,652	(1,070)*	34.9M	14.2 quarters	Q2 FY26 10-QMar 31, 2026
Neogenomics	139,281	209,254	(8,885)*	129.4M	18.9 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.